Supernus Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Supernus Pharmaceuticals, Inc.
US FDA told the company to add a warning to the label in late January, about a month before the generic refill cartridge was approved.
Keeping Track: Spectrum Submits Poziotinib; US FDA Approves Daré’s Xaciato, Expands Heron Zynrelef Label
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
ICER's report on unsupported price increases highlighted seven drugs that cost the US health system $1.67bn due to price increases after rebates and other concessions.
Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.
- Specialty Pharmaceuticals
- Controlled Release
- Other Names / Subsidiaries
- Adamas Pharmaceuticals, Inc.
- Biscayne Neurotherapeutics, Inc.
- Biscayne Neurotherapeutics Australia Pty, Ltd
- Shire plc
- Shire Laboratories Inc